LAP Inhibitors Modulate Tumor Microenvironment via Autophagy Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively targeting and reducing tumor size or number due to the heterogeneity of cancer cells and the complexity of cellular signaling pathways, particularly in modulating the LAP pathway which is distinct from canonical autophagy.
Innovation Solution
The development of compositions and methods that target the LAP pathway by administering LAP inhibitors to modulate the tumor microenvironment, enhancing the cytotoxic immune response by manipulating effector T cells and increasing Th1 responses, thereby reducing tumor size or number.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapeutic agents are used to treat cancer, then some tumor cells may be killed, but cancer cell heterogeneity leads to treatment resistance and tumor recurrence
Solution Approach 1:
The patent segments the complex cancer treatment approach by targeting specific molecular pathways (LAP pathway components like ATG16L1, IRGM, TBK1) rather than using broad-spectrum chemotherapy. This allows for precise intervention in tumor suppressor mechanisms while sparing normal cells, thereby overcoming the limitation of treating heterogeneous cancer cells with non-specific agents
Solution Approach 2:
The invention changes the therapeutic parameter from general cytotoxicity to specific modulation of autophagy-related gene expression and LAP pathway activity. By altering the molecular parameters of tumor suppression through targeted pathway modulation, the treatment becomes effective against diverse cancer cell types that would otherwise resist conventional chemotherapy
2Volume of stationary object
If the LAP pathway is modulated to suppress tumors, then tumor size or number is reduced, but the complexity of cellular signaling pathways makes targeted intervention difficult
Solution Approach 1:
The patent extracts and isolates specific LAP pathway components (ATG16L1, IRGM, TBK1, NDP52) from the complex cellular signaling network. By focusing on these discrete molecular targets, the invention simplifies the intervention strategy while achieving effective tumor suppression through modulation of the LAP pathway without needing to control the entire signaling cascade
Solution Approach 2:
The invention uses small molecule compounds as intermediaries to modulate LAP pathway activity. These compounds serve as mediators that can selectively influence the expression or function of LAP pathway components, thereby translating the complex molecular interactions into a controllable therapeutic effect that reduces tumor burden
3Power
If LAP inhibitors are administered to enhance cytotoxic immune response, then Th1 response and IFNγ/TNFα expression increase, but specificity in targeting LAP pathway versus canonical autophagy is challenging
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target LAP pathway components in immunorelevant contexts while preserving canonical autophagy function. The selective modulation of ATG16L1, IRGM, TBK1, or NDP52 in immune cells enhances Th1 response and cytotoxic activity without disrupting the essential autophagic processes required for cellular homeostasis
Solution Approach 2:
Instead of directly inhibiting LAP pathway components, the invention uses compounds that modulate the expression or activity of these components in a manner that enhances immune function. By inverting the traditional inhibition approach to use positive modulation of LAP pathway genes, the treatment achieves enhanced Th1 response and tumor suppression while maintaining pathway specificity
Data Source
AI summary
Compositions and methods are provided for suppressing tumors by modulating the LAP pathway. Targeting components of the LAP pathway for specific drug design can be used as n immunotherapy strategy that modulates the tumor microenvironment. It is well established that infiltrating monocytes and macrophages play a pivotal role in shaping an immunosuppressive tumor microenvironment. By modulating LAP in the innate immune cells, the function of effector T cells can be manipulated toward an effective, cytotoxic immune response that can eliminate tumor cells. Thus, methods are provided for reducing the size or number of tumor cells and for treating cancer or other cell proliferative disorders. Further provided are methods for increasing the Th1 response or increasing IFNγ and/or TNFα expression in the tumor microenvironment by administering a LAP inhibitor.